SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gufic Biosciences - Quaterly Results

10 Feb 2023 Evaluate
The quarter ended December 2022 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 1774.73 millions.The Net Profit of the company registered a slight decline of -3.32% to Rs. 203.36  millions from Rs. 210.34 millions.A decline of 341.49 millions was observed in the OP in the quarter ended December 2022 from 342.49 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 1774.73 1720.65 3.14 5175.84 6169.62 -16.11 7791.56 4876.99 59.76
Other Income 7.57 15.30 -50.52 19.50 30.63 -36.34 31.04 37.33 -16.85
PBIDT 341.49 342.49 -0.29 1011.34 1172.59 -13.75 1488.20 876.53 69.78
Interest 21.60 10.32 109.30 46.74 37.90 23.32 48.47 136.33 -64.45
PBDT 319.89 332.17 -3.70 964.60 1134.69 -14.99 1439.73 740.20 94.51
Depreciation 47.41 44.84 5.73 136.70 128.07 6.74 171.34 163.08 5.06
PBT 272.48 287.33 -5.17 827.90 1006.62 -17.75 1268.39 577.12 119.78
TAX 69.12 76.99 -10.22 211.90 250.86 -15.53 309.98 134.80 129.96
Deferred Tax -0.38 4.29 -108.86 -8.20 -4.14 98.07 -11.52 20.11 -157.28
PAT 203.36 210.34 -3.32 616.00 755.76 -18.49 958.41 442.32 116.68
Equity 96.95 96.95 0.00 96.95 96.95 0.00 96.94 96.94 0.00
PBIDTM(%) 19.24 19.90 -3.33 19.54 19.01 2.81 19.10 17.97 6.27

Gufic Biosciences Share Price

301.70 -0.95 (-0.31%)
17-Apr-2026 10:38 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1689.10
Dr. Reddys Lab 1221.40
Cipla 1239.90
Zydus Lifesciences 946.80
Lupin 2333.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×